Using immunohistochemistry to quantify the amount of Cornulin in both suspected cSCC samples and regional lymph nodes could assist with the current morphology-driven diagnostic methods and aid in detecting both primary lesions and micrometastasis, thus improving clinical outcomes and survival rates for these patients. The gene discussed is CRNN; the disease is skin squamous cell carcinoma.